HyTest Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HyTest Ltd. - overview
Established
1994
Location
Turku, -, Finland
Primary Industry
Biotechnology
About
Based in Turku, Finland, and founded in 1994, HyTest Ltd. develops and supplies immunological reagents for the IVD industry and research community. In September 2018, Summa Equity acquired a majority stake in HyTest Ltd. and in May 2021, Shenzhen Mindray Bio-Medical Electronics Co.
, Ltd. acquired HyTest Ltd. for approximately EUR 545 million. As of 2024, the company is led by its CEO, Netta (Fatal) Keinänen.
The company’s product category for the IVD industry includes monoclonal antibodies, polyclonal antibodies, sera, plasma, and antigens. The company’s clinical area-based products include cardiac markers, blood coagulation and anaemia, metabolic syndrome, kidney diseases, fertility and pregnancy, hormones, tumor markers, neuroscience, immunology and serology, inflammation, infectious diseases, veterinary, microbial, and plant toxins, biodefense, miscellaneous, and gangliosides.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.hytest.fi/
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.